Compare JEF & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JEF | CORT |
|---|---|---|
| Founded | 1968 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0B | 9.7B |
| IPO Year | 2014 | 2001 |
| Metric | JEF | CORT |
|---|---|---|
| Price | $55.73 | $95.41 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 5 |
| Target Price | $61.40 | ★ $96.50 |
| AVG Volume (30 Days) | ★ 2.0M | 1.1M |
| Earning Date | 03-25-2026 | 04-30-2026 |
| Dividend Yield | ★ 3.37% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.70 | N/A |
| Revenue | ★ $10,823,677,000.00 | $761,407,000.00 |
| Revenue This Year | $13.23 | $26.08 |
| Revenue Next Year | $10.25 | $26.98 |
| P/E Ratio | $79.40 | ★ N/A |
| Revenue Growth | 2.93 | ★ 12.79 |
| 52 Week Low | $35.53 | $28.66 |
| 52 Week High | $71.04 | $97.05 |
| Indicator | JEF | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 52.65 | 63.30 |
| Support Level | $51.39 | $76.41 |
| Resistance Level | $58.32 | N/A |
| Average True Range (ATR) | 1.73 | 4.17 |
| MACD | 0.27 | -0.36 |
| Stochastic Oscillator | 76.76 | 81.02 |
Jefferies Financial Group is a full-service investment banking and capital markets firm that was founded in 1962. After nearly 30 years of focusing on institutional trading services, it entered the investment banking industry in the early 1990s, which ultimately grew into the core business. In 2013, Jefferies merged with Leucadia, a manufacturing-focused holding company. Since the merger, Jefferies became the core of the combined business as the bulk of the legacy portfolio was sold off and the parent company was renamed to match the subsidiary. Within the investment banking landscape, Jefferies predominately serves the North American middle market and has captured considerable market share over the past decade.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.